Nishigaki F, Miyayasu K, Tsujimoto S, Manda T, Shimomura K
Department of Pharmacology, Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan.
Anticancer Res. 1994 Nov-Dec;14(6B):2573-6.
Recombinant tumor necrosis factor-alpha (rTNF-alpha) inhibited tumor growth of Meth A fibrosarcoma (Meth A) solid tumor in mice, and the antitumor effect of rTNF-alpha was significantly decreased by pretreatment with small doses or rTNF-alpha in mice. In in vitro experiments, incubation of human umbilical vein endothelial cells with rTNF-alpha enhanced procoagulant activity (PCA), which was drastically augmented after an addition of the conditioned medium of Meth A tumor cells. Furthermore, rTNF-alpha-induced PCA was decreased by pretreatment with rTNF-alpha in endothelial cells. This PCA was completely blocked after the addition of anti-human tissue factor (TF) murine monoclonal antibody. These results imply that in vivo antitumor effects of rTNF-alpha are mediated by expression of TF in endothelial cells, which is augmented by tumor released factor(s).
重组肿瘤坏死因子-α(rTNF-α)可抑制小鼠体内Meth A纤维肉瘤(Meth A)实体瘤的生长,而小剂量rTNF-α预处理可显著降低rTNF-α在小鼠体内的抗肿瘤作用。在体外实验中,用rTNF-α孵育人脐静脉内皮细胞可增强促凝活性(PCA),在添加Meth A肿瘤细胞的条件培养基后,促凝活性急剧增强。此外,内皮细胞用rTNF-α预处理后,rTNF-α诱导的PCA降低。添加抗人组织因子(TF)鼠单克隆抗体后,这种PCA被完全阻断。这些结果表明,rTNF-α在体内的抗肿瘤作用是由内皮细胞中TF的表达介导的,而肿瘤释放的因子可增强TF的表达。